Loading...
NXTC
XNAS
Market cap29mUSD
Nov 20, Last price  
6.45USD
1D
-4.87%
1Q
2.54%
IPO
-97.24%
Name

NextCure Inc

Chart & performance

D1W1MN
XNAS:NXTC chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
170.91%
Shs. 5Y
4.38%
Rev. 5Y
52.18%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
006,347,00022,378,00000000
Net income
-56m
L+0.34%
-15,469,000-22,799,000-33,737,000-36,603,000-69,389,000-74,733,000-62,723,000-55,654,000-55,844,000
CFO
-50m
L+21.59%
-12,514,0007,992,000-35,623,000-44,954,000-57,244,000-53,886,000-52,974,000-40,805,000-49,613,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.

Key people

David Kabakoff
Independent Chairman of the Board · since 2015
Steven Cobourn
Chief Financial Officer · since 2018
Timothy Mayer
Chief Operating Officer · since 2019
Sourav Kundu
Senior Vice President - Development and Manufacturing · since 2021
Kevin Shaw
Senior Vice President, General Counsel · since 2023
Udayan Guha
Chief Medical Officer · since 2025
President, Chief Executive Officer, Director · since 2015
Independent Director · since 2021
Independent Director · since 2021
John Houston
Independent Director · since 2020
Independent Director · since 2015
Independent Director · since 2019
IPO date
May 09, 2019
Employees
99
Domiciled in
US
Incorporated in
US
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
9000 Virginia Manor Road
Suite 200
Beltsville, MD 20705
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT